Wird geladen...
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
Immunotherapy has shown promising results in cancer treatment. Research shows that most patients might be resistant to these therapies. So, new immune therapies are needed. OX40 (CD134) and OX40 ligand (OX40L), costimulatory molecules, express on different types of immune cells. The interaction betw...
Gespeichert in:
| Veröffentlicht in: | Onco Targets Ther |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735535/ https://ncbi.nlm.nih.gov/pubmed/31564917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S214211 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|